¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"effective lethal phase"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • effective temperature index
    À¯È¿¿ÂµµÁö¼ö
  • individual effective dose
    °³ÀÎÀ¯È¿¿ë·®
  • minimal effective analgesic concentration
    ÃÖ¼ÒÈ¿°úÁøÅë³óµµ
  • minimal effective dose
    ÃÖ¼ÒÀ¯È¿·®
  • mean effective dose
    Æò±ÕÀ¯È¿¼±·®
  • median effective dose
    1. Áß°£À¯È¿¿ë·® 2. Áß°£À¯È¿¼±·®
  • acceleration phase
    ÃËÁø±â, °¡¼Ó±â
  • active phase
    Ȱ¼º±â
  • acute phase reactant
    ±Þ¼º±â¹ÝÀÀ¹°Áú
  • acute phase reaction
    ±Þ¼º±â¹ÝÀÀ
  • acute phase serum
    ±Þ¼º±âÇ÷û
  • advanced sleep phase syndrome
    ÀüÁø¼ö¸éÀ§»óÁõÈıº
  • anal-sadistic phase
    Ç×¹®°¡Çбâ
  • bulk phase model
    µ¢¾î¸®À§»ó¸ðÇü
  • circadian-phase intervention
    ÇÏ·çÁÖ±âÀ§»óÁßÀç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • effective circulating volume
    À¯È¿¼øÈ¯¿ëÀû
  • effective dose equivalent
    À¯È¿¼±·®ÇØ´ç·®
  • effective filtration pressure
    À¯È¿¿©°ú¾Ð
  • effective membrane resistance
    À¯È¿¸·ÀúÇ×
  • effective perceived noise level
    ½ÇÈ¿°¨¼ö¼ÒÀ½¼öÁØ, ½ÇÁ¦°¨°¢¼ÒÀ½
  • effective quantum number
    À¯È¿¾çÀÚ¼ö
  • effective renal blood flow
    À¯È¿ÄáÆÏÇ÷·ù·®
  • effective renal plasma flow
    À¯È¿ÄáÆÏÇ÷Àå·ù·®
  • effective temperature index
    À¯È¿¿ÂµµÁö¼ö
  • 3D phase contrast angiography
    »ïÂ÷¿øÀ§»ó´ëÁ¶Ç÷°üÁ¶¿µ¼ú
  • acceleration phase
    ÃËÁø±â, °¡¼Ó±â
  • acute phase reactant
    ±Þ¼º±â¹ÝÀÀ¹°Áú
  • acute phase reaction
    ±Þ¼º±â¹ÝÀÀ
  • acute phase serum
    ±Þ¼º±âÇ÷û
  • advanced sleep phase syndrome
    ÀüÁø¼ö¸éÀ§»óÁõÈıº
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • full erection phase
    ¿ÏÀü¹ß±â±â
  • g0 phase
    Á¤Áö±â G0±â
  • g1 phase
    ÇÕ¼ºÀü±â G1±â
  • g2 phase
    ÇÕ¼ºÈıâ G2±â
  • gastric phase
    À§»ó(êÖßÓ) À§»êºÐºñ(êÖߤÝÂÝô)ÀÇ .
  • go phase
    Á¤Áö±â Go±â
  • gradient induced phase shift effect
    °æ»ç À¯µµ À§»ó º¯À§ È¿°ú
  • grinding phase
    ºÐ¼â»ó.
  • implantational phase
    Âø»ó±â
  • in-phase image
    À§»ó³» ¿µ»ó
  • inactive phase
    ºñȰµ¿±â
  • inadequate luteal phase
    Ȳü±âºÎÀü(üÜô÷ÐïÝÕîï).
  • inadequate luteal phase
    Ȳü±âºÎÀü(üÜô÷ÐïÝÕîï).
  • inspiratory phase
    Èí±â»ó(ýåѨßÓ).
  • inspiratory phase time
    Èí±â»ó½Ã°£.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • minimum lethal dose (MLD)
    ÃÖ¼ÒÄ¡»ç·®
  • mutant, conditional lethal
    Á¶°ÇÄ¡»ç µ¹¿¬º¯ÀÌÁÖ
  • potentially lethal damage repair
    ÀáÀçÄ¡»ç¼Õ»óȸº¹
  • tumor lethal dose
    Á¾¾çÄ¡»ç·®(ðþåËöÈÞÝåÖ)
  • biologically effective dose
    »ý¹°ÇÐÀûÀ¯È¿¼±·®
  • collective effective dose
    Áý´ÜÀ¯È¿¼±·®
  • committed effective dose
    ¿¹Å¹À¯È¿¼±·®
  • committed effective dose equivalent
    ¿¹Å¹À¯È¿¼±·®´ç·®
  • effective TR
    À¯È¿ ¹Ýº¹ ½Ã°£
  • effective alveolar air
    À¯È¿ÆóÆ÷°ø±â(êóüùøËøàÍöѨ).
  • effective alveolar ventilation =EAV
    À¯È¿ÆóÆ÷ȯ±â(·®)(êóüùøËøàüµÑ¨åÖ) .
  • effective blood volume
    À¯È¿Ç÷¾×·®(êóüùúìäûÕá).
  • effective blood volume
    À¯È¿Ç÷¾×·®.
  • effective capacity
    À¯È¿¿ë·®.
  • effective charge
    À¯È¿ÀüÇÏ(¡­ï³ùÃ).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Luteal phase
    Ȳ(»ö)ü±â
    [¿¾ ¿ë¾î] Ȳü±â
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • one-phase chromatography
    ÀÏ»ó(ìéßÓ) Å©·Î¸¶Åä±×·¡ÇÇ
  • partition phase
    ºÐ¹è»ó(ÝÂÛÕßÓ)
  • phase
    »ó(ßÓ)
  • phase contrast microscope
    À§»óÂ÷(êÈßÓó¬) Çö¹Ì°æ(ßÓÓßðÎúéÚ°Ìð)
  • phase partition
    »óºÐ¹è(ßÓÝÂÛÕ)
  • phase plate
    »óÆÇ(ßÓ÷ù)
  • phase rule
    »óÀ²(ßÓëÏ)
  • phase shift mutation
    »óÀ̵¿ º¯ÀÌ(ßÓì¹ÔÑܨì¶)
  • phase test
    »ó½ÃÇè(ßÓãËúÐ)
  • phase transfer
    »óÀüÀÌ(ßÓï®ì¹)
  • phase variation
    »óº¯µ¿(ßÓܨÔÑ)
  • preinductive phase
    ÀüÀ¯µµ±â(îñë¯ÓôÑ¢)
  • productive phase
    »ý»ê±â(ßæß§Ñ¢)
  • reduction phase
    ȯ¿ø±â(ü½êªÑ¢)
  • regeneration phase
    Àç»ý±â(î¢ßæÑ¢)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • phase encoding
    À§»óºÎȣȭ
  • phase encoding gradient
    À§»óºÎȣȭ°æ»çµµ(Àå)
  • phase encoding step
    À§»óºÎÈ£´Ü°è
  • phase evolution of fat suppression
    À§»ó¼±È¸ Áö¹æ¾ïÁ¦
  • phase frequency swap
    À§»óÁ֯ļö±³È¯
  • phase image
    À§»ó¿µ»ó
  • phase mismapping
    À§»ó¿ÀÁöµµÀÛ¼º
  • phase offset multiplannar [=POMP] imaging
    À§»ó¿ÀÇÁ¼Â´Ù¸é¿µ»ó
  • phase sensitive technique description
    À§»ó¹Î°¨¹ý¼³¸í
  • phase shift
    À§»óº¯À§
  • phase shift artifact
    À§»óº¯À§Àΰø¹°
  • phase shift effect
    À§»óº¯À§È¿°ú
  • phase wrap
    À§»óÆ÷Àå
  • phase wraparound
    À§»óÆ÷Àå
  • phase wraparound artifact
    À§»óÆ÷ÀåÀΰø¹°
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
LD50 Median Lethal Dose; ¹ÝÄ¡»ç·®
LF   1) Lethal Factor
  2) Line Feed
  3) Left Foot
MLC   1) Minimal Lethal Concentration
  2) Mixed Lymphocyte Culture
PLD POtentially Lethal Damage
SLD Sub-Lethal Damage
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
E(a) Effective arterial elastance
EC50 Effective concentrations
ED Effective doses
EHBF Effective hepatic blood flow
ERP Effective refractory period
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • arterial phase
    µ¿¸Æ ±â
  • bacterial phase
    ¼¼±Õ »ó
    ¼¼±ÕÀÌ ´«¿¡ º¸ÀÌ´Â ¾ç»ó.
  • closing phase
    Æó±¸ ´Ü°è
  • dispersed phase
    ºÐ»ê »ó
  • equilibrium phase diagram
    ÆòÇü »óŵµ
    ÇÕ±ÝÀÇ Á¶¼º°ú ¿Âµµ°¡ ¹Ù²î¾îÁ³À» ¶§ÀÇ ÆòÇü »óÅ¿¡¼­ÀÇ »óÀÇ º¯È­¸¦ º¸ÀÎ ±×¸².
  • expiratory phase
    È£±â
  • exponential phase of growth
    ´ë¼ö Áõ½Ä±â, °¡¼Ó ¼ºÀå±â
  • implant surgical phase
    ¸Å½Ä ¿Ü°úÀû ´Ü°è
    ¸Å½Ä ÀÇÄ¡¸¦ Á¦ÀÛÇϱâ À§ÇÏ¿© Á¦1´Ü°èÀû »óÅ·Î, °ñ¸·À» ¾Ç°ñ¿¡¼­ ºÐ¸®ÇÏ¿© °ñ¸·ÀÌ ³ëÃâµÈ »óÅÂÀε¥ ¿©±â¼­ ÀλóÀÌ Ã¤µæµÈ´Ù. Á¦ 2´Ü°è´Â ±× °ñ¸é¿¡ ±Ý¼Ó ¸Å½Ä¹°À» ³õ°í ´Ù½Ã ºÀÇÕÇÏ¿© ¸Å½Ä¹°ÀÇ Áö´ëÄ¡°¡ ¿ÜºÎ·Î ³ëÃâµÇµµ·Ï ÇÏ´Â ´Ü°è. ÀÌ»óÀÇ µÎ ´Ü°è¸¦ ÀÏÄ´´Ù.
  • isotonic contraction phase
    µî·Â ¼öÃà±â
  • lactiferous phase
    ¼öÀ¯±â
  • lag phase
    ½Ãµ¿±â
  • late luteal phase dysphoric disorder
    ¸»±â Ȳü±â ºÒÄè Àå¾Ö
  • latency phase
    Àẹ±â
    º´¼Ò°¡ ħÀÔÇØ¼­ Áï½Ã °¨¿°À» ÀÏÀ¸Å°´Â °ÍÀÌ ¾Æ´Ï°í ¼÷ÁÖ ³»¿¡ ±â»ýÇϸ鼭 ÀûÀÀÇØ¼­ °¨¿°ÀÇ Áõ»óÀ» ³ªÅ¸³»±â±îÁöÀÇ ½Ã°£.
  • life phase
    »ýȰ»ó
  • luteal phase
    ¿ù°æ ÁÖ±âÁß È²Ã¼±â, Ȳü ´Ü°è, Ȳü±â
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
lethal dose 50 <pharmacology> The amount, or dosage, of a toxin necessary to kill 50% of the experimental subjects.
(16 Mar 1998)
lethal dwarfism Dwarfism leading to intrauterine or neonatal death.
(05 Mar 2000)
lethal equivalent A combination of selective effects that on average have the same impact on the composition of the gene pool as one death; e.g., two carriers at 50% risk of dying would be the lethal equivalent of one carrier at 100% risk, in the population genetics of recessive traits lethal equivalent is expressed as twice the sum of the expected number of deaths ascribable to the genetic load.
Expression used of the genetic load of recessive genes in heterozygous state that if in homozygous state would cause death or carry a risk of death. The expected number of deaths from all such genes is expressed in lethal equivalent.
(05 Mar 2000)
lethal factor A disorder that prevents effective reproduction by those affected; e.g., Klinefelter syndrome.
(05 Mar 2000)
lethal gene A gene that produces a genotype that leads to death of the organism before reproduction is possible or that precludes reproduction; for a recessive gene the homozygous or hemizygous state is lethal.
(05 Mar 2000)
lethal midline granuloma Destruction of the nasal septum, hard palate, lateral nasal walls, paranasal sinuses, skin of the face, orbit and nasopharynx by an inflammatory infiltrate with atypical lymphocytic and histiocytic cells; presumably a form of lymphoma in most cases.
An obsolete term for polymorphic reticulosis.
Synonym: granuloma gangrenescens, malignant granuloma, midline malignant reticulosis granuloma.
(05 Mar 2000)
lethal mutation <genetics, molecular biology> Mutation that eventually results in the death of an organism carrying the mutation.
(18 Nov 1997)
accelerated phase of leukaemia Refers to chronic myelogenous leukaemia that is progressing. The number of immature, abnormal white blood cells in the bone marrow and blood is higher than in the chronic phase, but not as high as in the blast phase.
(12 Dec 1998)
acceleration phase <cell biology, cell culture> A period of increasing growth before the log phase in a culture of microbes.
After the culture is started on a medium, at first there is no growth (the lag phase) and then the microbes start to gradually grow (acceleration phase) until they reach a constant maximum rate of growth (log phase).
(15 Jan 1998)
acute-phase protein <haematology> These plasma proteins (in addition to fibrinogen) increase 25% or more in response to inflammation and injury are under direct control of interleukin-6 (IL-6) (hepatocyte-stimulating factor).
Other proteins which increase are ceruloplasmin, C3 and C4 which increase 50% or more; alpha-1 acid glycoprotein, alpha-1 antitrypsin, haptoglobin and fibrinogen (the major determinant of viscosity 1 ) which increase two- to fourfold; C-reactive protein (CRP) and serum amyloid A which increase several hundred-fold.
Despite long-held clinical opinion to the contrary, available data indicate that neither ESR nor measurement of specific acute-phase reactants are useful in excluding underlying infection or inflammation regardless of the pretest probability.
These proteins are secreted into the blood in increased or decreased quantities by hepatocytes in response to trauma, inflammation, or disease. They can serve as inhibitors or mediators of the inflammatory processes. Certain acute-phase proteins have been used to diagnose and follow the course of diseases or as tumour markers.
See also: amyloid, c-reactive protein, erythrocyte sedimentation rate, viscosity.
(25 Jun 1999)
acute-phase reaction <immunology, rheumatology> Refers to the changes in synthesis of certain proteins within the serum during an inflammatory response, which provides rapid protection for the host against microorganisms via non-specific defense mechanisms.
It consists of fever, an increase in inflammatory humoral factors, and an increased synthesis by hepatocytes of a number of proteins or glycoproteins usually found in the plasma; the reaction is mediated by endogenous pyrogens, the hypothalamus, adrenal hormones, and other factors.
(12 Jul 2000)
anal phase In psychoanalytic personality theory, the stage of psychosexual development, occurring when a child is between 1 and 3 years, during which activities, interests, and concerns are centreed around the anal zone.
(05 Mar 2000)
aqueous phase The water portion of a system consisting of two liquid phase's, one mainly water, the other a liquid immiscible with water (e.g., benzene, ether).
(05 Mar 2000)
blast phase Refers to advanced chronic myelogenous leukaemia. In this phase, the number of immature, abnormal white blood cells in the bone marrow and blood is extremely high. Also called blast crisis.
(12 Dec 1998)
g0 phase Phase of the cell cycle where cells exist in a quiescent state. These cells have unduplicated DNA, degraded RNA and protein, and low enzyme activity. The ability to switch between g0 and g1 (and vice versa) determines the post-embryonic cell proliferation rate and is defectively controlled in neoplastic cells.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á